Since immune checkpoint inhibitors block PD-1/PD-L1 inhibitory signals on cytotoxic T cells to induce subsequent clinical benefit [24, 25], it is not strange that successful treatment strategies require sufficient T cells in the tumor bed [4, 26]. Here, PDCD1 is linked to neoplasm.